News Release

Evidence suggests bubonic plague had long-term effect on human immunity genes

Scientists examined DNA from mass grave of plague victims in Germany

Peer-Reviewed Publication

University of Colorado Anschutz Medical Campus

AURORA, Colo. (May 6, 2021) - Scientists examining the remains of 36 bubonic plague victims from a 16th century mass grave in Germany have found the first evidence that evolutionary adaptive processes, driven by the disease, may have conferred immunity on later generations of people from the region.

"We found that innate immune markers increased in frequency in modern people from the town compared to plague victims," said the study's joint-senior author Paul Norman, PhD, associate professor in the Division of Personalized Medicine at the University of Colorado School of Medicine. "This suggests these markers might have evolved to resist the plague."

The study, done in conjunction with the Max Planck Institute in Germany, was published online Thursday in the journal Molecular Biology and Evolution.

The researchers collected DNA samples from the inner ear bones of individuals in a mass grave in the southern German city of Ellwangen which experienced bubonic plague outbreaks in the 16th and 17th centuries. Then they took DNA samples from 50 current residents of the town.

They compared their frequency spectra - the distribution of gene variants in a given sample - for a large panel of immunity-related genes.

Among the current inhabitants, the team found evidence that a pathogen, likely Yersinia pestis which causes bubonic plague, prompted changes in the allele distribution for two innate pattern-recognition receptors and four Human Leukocyte Antigen molecules, which help initiate and direct immune response to infection. An allele is a variant form of a gene.

"We propose that these frequency changes could have resulted from Y.pestis plague exposure during the 16th century," Norman said.

The findings are the first evidence that evolutionary processes, prompted by Y. pestis, may have been shaping certain human immunity-relevant genes in Ellwangen and possibly throughout Europe for generations.

And since the plague tormented Europe for nearly 5,000 years, the study suggests that these immunity genes may have been pre-selected in the population long ago but recently became selected through epidemic events.

"Although the lethality of the plague is very high without treatment it remains likely that specific individuals are protected from, or more susceptible to, severe disease through polymorphism in the determinants of natural immunity," the study said. "In this case, any change in allele frequencies that occurred during a given epidemic crisis could be evident as genetic adaptation and detectable in modern day individuals."

Later simulations showed that natural selection likely drove these allele frequency changes.

"I think this study shows that we can focus on these same families of genes in looking at immunity in modern pandemics," Norman said. "We know these genes were heavily involved in driving resistance to infections."

The study also demonstrates that, so far, no matter how deadly the pandemic there are always survivors.

"It sheds light on our own evolution," Norman said. "There will always be people who have some resistance. They just don't get sick and die and the human population bounces back."

Still, he doesn't want people to get the wrong message, especially in the era of Covid-19.

"I wouldn't want to discourage anyone from taking a vaccine for the current pandemic," Norman said. "It's a much safer bet than counting on your genes to save you."

###

About the University of Colorado Anschutz Medical Campus

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education, and healthcare. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked hospitals that treat more than 2 million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, together we deliver life-changing treatments, patient care, professional training, and conduct world-renowned research powered by more than $500 million in research awards. For more information, visit https://www.cuanschutz.edu


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.